Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokKorai 1. fázis

An fMRI Investigation of the Effects of IV Lidocaine on Tinnitus

A legfontosabb adatok

Ki végzi
D. Bradley Welling, MD, PhD
Hol
Boston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
Korai 1. fázis
Résztvevők
40 fő, tervezett
Kezdés
2021. ápr. 28.
Várható befejezés
2027. dec. 31.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • IV Lidocaine
A regiszteradat frissítve
2025. december 2.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with tinnitus (ringing in the ears), with or without hearing loss. It also takes people with normal hearing and no tinnitus as a comparison group. Everyone gets IV lidocaine and brain scans (fMRI).

Életkor
18 years and older
Nem
All sexes
A betegség stádiuma
One of four groups: normal hearing without tinnitus; normal hearing with tinnitus; hearing loss and tinnitus in one ear; or hearing loss and tinnitus in both ears. Tinnitus must be there often or always. Normal hearing means hearing tests at 25 dB or less. Hearing loss means 50 dB or greater across 3 frequencies.
Korábbi kezelés
People now taking medicines for tinnitus cannot join, unless they stop them for 60 days first. No antibiotics within 48 hours of the infusion. No current heart rhythm medicines (antiarrhythmics).

A részvétel fő kizáró okai

  • Cannot have an fMRI scan, for example fear of closed spaces or metal in the body that cannot be removed
  • Allergy to lidocaine, past heart attack, or heart rhythm problems without a pacemaker
  • History of seizures, or other brain or mental health conditions such as stroke or schizophrenia
  • Resting blood pressure below 100/50, or known liver failure
  • Pregnant or breastfeeding women

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • -Age ≥ 18
  • Ability to provide informed consent
  • English speaker
  • Falls under one of the four groups a. Normal Hearing without Tinnitus (NH/T-) i. Normal Hearing as defined as pure tone thresholds of 25 dB or less across all tested frequencies ii. Subjective confirmation of lack of tinnitus* 1. Never or rarely b. Normal Hearing with Tinnitus (NH/T+) i. Normal Hearing Normal Hearing as defined as pure tone thresholds of 25 dB or less across all tested frequencies ii. Subjective confirmation of tinnitus* 1. Often, always c. Unilateral hearing loss and ipsilateral unilateral tinnitus (uHL/uT+) i. Unilateral hearing loss as defined by pure tone thresholds of 50 dB or greater across 3 frequencies in the bad ear and 25 dB or less in good ear ii. Subjective confirmation of tinnitus in the good ear* 1. Often, always d. Bilateral hearing loss and bilateral tinnitus (bHL/bT+) i. Bilateral hearing loss as defined by pure tone thresholds of 50 dB or greater across 3 frequencies in both ears ii. Subjective confirmation of tinnitus in both ears*; Often, always; Tinnitus will be confirmed via Likert-scale: Never - Rarely - Sometimes - Often - Always

Ki nem vehet részt

  • Currently undergoing tinnitus treatment with other pharmacologic agents; Patients may be eligible if they complete a 60 day washout period from pharmacologic agents treating tinnitus
  • Currently taking antiarrhythmics
  • Contraindications to IV lidocaine administration such known allergy to lidocaine
  • History of myocardial infarction or cardiac arrhythmias including Wolff-Parkinson-White, severe sinoatrial, atrioventricular or intraventricular heart block in the absence of a pacemaker
  • History of seizure disorder
  • Known hepatic failure
  • Patient with other neurological or psychiatric disorders, such as stroke, brain tumor, schizophrenia, bipolar disorder
  • Inability to tolerate fMRI or other contraindications of fMRI including claustrophobia or presence of ferromagnetic objects in the body that cannot be removed
  • Resting BP of <100/50
  • Have taken antibiotics within 48 hours of infusion
  • Pregnant or lactating women
  • Patients who cannot fill out the questionnaires

Helyszínek itt: Egyesült Államok

  • Massachusetts Eye and Ear InfirmaryBoston, Egyesült ÁllamokContact: Azadeh Hamzehei Sichani, MD, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is an exploratory pilot open-label study to identify the signal changes on fMRI of patients with tinnitus and with temporary suppression of the tinnitus with IV lidocaine. Patients will include those with hearing loss (both unilateral and bilateral) and tinnitus, subjects with normal hearing and tinnitus, and control subjects with normal hearing and no tinnitus. Eligible subjects will have functional and subjective data collected at baseline, receive an IV lidocaine infusion, and have functional and subjective data collected post-infusion for comparison and identification of involved neural networks.

A vizsgálat csoportja

  • IV lidocaineA vizsgált kezelés

    1000mg/hour IV lidocaine administered for up to 30 minutes (500mg max). Patients will be continuously monitored by a nurse every 5 (±2) minutes to check specifically for vital signs (BP, HR, and RR), patient tinnitus levels, and reports of side effects. The infusion is continued until any of the following criteria are met: 1) the patient has completed the 30-minute infusion; 2) the patient reports intolerable or concerning side effect, such as dizziness, nausea, or vomiting; 3) the patient experiences bradycardia \<50 and a drop of systolic blood pressure (BP) more than 20 mmHg and diastolic pressure more than 10 mmHg during the infusion; 4) the patient reports that tinnitus is resolved, or 5) the patient wishes to stop the study. Serum lidocaine levels will be drawn by a research nurse upon completion of MRI. The Tinnitus Handicap Inventory, the Tinnitus Functional Index, and the Visual Analog Scale will be administered after IV infusion.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. december 2.